Effects of combined dietary supplementation on oxidative and inflammatory status in dyslipidemic subjects.
OBJECTIVE
Dyslipidemia is one of the main risk factors for atherosclerosis, usually the underlying cause of cardiovascular diseases which are the major cause of morbidity and mortality in developed countries. The aim of this study was to assess the effects and the advantages of a combined dietary supplementation with PUFA n-3, vitamin E, niacin and gamma-oryzanol on lipid profile, inflammatory status and oxidative balance.


RESULTS
Fifty-seven dyslipidemic volunteers were randomly assigned to receive: placebo (group A, 19 subjects); PUFA n-3 and vitamin E (group B, 18 subjects); the same as B plus gamma-oryzanol and niacin (group C, 20 subjects). Lipid profile, reactive oxygen species (ROS), total antioxidant capacity (TAC), vitamin E, interleukin 1-beta (IL1-beta), tumor necrosis factor (TNF-alpha) and thromboxane B2 (TXB2) were determined at baseline (T0) and after four months (T1). All dyslipidemic subjects showed, at baseline, oxidative stress and, after four months, all biochemical markers improved significantly in groups treated with dietary supplementation. Particularly in group C all lipid patterns improved significantly.


CONCLUSIONS
Our findings demonstrate that the strategy of combining different compounds, which protect each other and act together at different levels of the lipid chain production, improves lipid profile, inflammatory and oxidative status, allowing us to reduce the dose of each compound under the threshold of its side effects.
Institute of Clinical Physiology CNR, Niguarda Cà Granda Hospital, Piazza Ospedale Maggiore, 3, 20162 Milan, Italy. accinni@tin.it
R
R
Accinni
M
M
Rosina
F
F
Bamonti
C
C
Della Noce
A
A
Tonini
F
F
Bernacchi
J
J
Campolo
R
R
Caruso
C
C
Novembrino
L
L
Ghersi
S
S
Lonati
S
S
Grossi
S
S
Ippolito
E
E
Lorenzano
A
A
Ciani
M
M
Gorini
D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000453:epidemiology / Q000209:etiology; D016207:Cytokines / Q000378:metabolism; D019587:Dietary Supplements; D004359:Drug Therapy, Combination; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000378:metabolism; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000008:administration & dosage / Q000627:therapeutic use; D010084:Oxidation-Reduction; D018384:Oxidative Stress / Q000187:drug effects*; D010666:Phenylpropionates / Q000008:administration & dosage / Q000627:therapeutic use; D017382:Reactive Oxygen Species / Q000378:metabolism; D012307:Risk Factors; D014810:Vitamin E / Q000008:administration & dosage / Q000627:therapeutic use
D000975:Antioxidants; D016207:Cytokines; D015525:Fatty Acids, Omega-3; D000960:Hypolipidemic Agents; D018836:Inflammation Mediators; D010666:Phenylpropionates; D017382:Reactive Oxygen Species; D014810:Vitamin E; D009525:Niacin; C013172:gamma-oryzanol